Evaluation of oral bioavailability and anticancer potential of raloxifene solid lipid nanoparticles.

Abstract

The objective of the present investigation was formulation of raloxifene loaded solid lipid nanoparticles (R-SLN) for oral administration and evaluation of its anticancer potential in 7,12- dimethylbenzanthracene (DMBA)-induced breast cancer in Sprague-Dawley rats. Optimized R-SLN formulation prepared by modified micro-emulsion method resulted in R-SLN of 288.0±28.5 nm size and 95.56% entrapment efficiency. R-SLN exhibited in vitro prolonged release of raloxifene for 72 h in phosphate buffered saline. R-SLN was stable in simulated gastro-intestinal (GIT) fluids consisting of pH 1.2, pH 7.4, simulated gastric fluid and simulated intestinal fluid. A two-fold increase was observed in raloxifene oral bioavailability from R-SLN. R-SLN exhibited enhanced efficacy and chemopreventive activity over pure raloxifene as indicated by evaluation of tumor burden (P < 0.001) and tumor incidence (P < 0.001). The results indicate the potential of raloxifene solid lipid nanoparticles in optimizing chemoprevention of breast cancer by R-SLN.

Cite this paper

@article{Battani2014EvaluationOO, title={Evaluation of oral bioavailability and anticancer potential of raloxifene solid lipid nanoparticles.}, author={Somashekhar Battani and Harish Pawar and Sarasija Suresh}, journal={Journal of nanoscience and nanotechnology}, year={2014}, volume={14 8}, pages={5638-45} }